Cell Source

Cell Therapy Treatments Based on Immune Tolerance

Health Tech & Life Sciences
Public on OTC on May, 2014

Company Overview

Snapshot

Founded in September 2011, Cell Source operates with 11–50 employees. The company has raised $21.54M across one funding round. In May 2014, Cell Source became publicly listed on the OTC market.

Business overview

Cell Source is a biotechnology company specializing in cell therapy treatments that leverage immune tolerance. The company's core technology, the patented Veto Cell platform, utilizes white blood cells processed with FDA-approved cytokines to selectively modulate immune responses. These Veto Cells are designed to facilitate bone marrow and organ transplantation, and to treat blood cancers like lymphoma and congenital diseases such as sickle cell anemia. Cell Source primarily operates within the Health Tech & Life Sciences sector, focusing on pharmaceuticals and medical biotechnology, particularly in drugs discovery and development and biomaterials and tissue engineering.

Strategic signal

In May 2026, Cell Source presented breakthrough developments for mismatched donor stem cell and organ transplants, alongside off-the-shelf CAR-T cell therapy, at the. This presentation signals the company's continued progress in advancing its Veto Cell technology for critical therapeutic applications, highlighting its potential to address significant unmet medical needs in transplantation and cancer treatment.

Company Intelligence Q&A

What is Cell Source's primary focus?
Cell Source is a biotechnology company focused on developing cell therapy treatments based on the management of immune tolerance.
When did Cell Source become a public company?
Cell Source became publicly listed on the OTC market in May 2014.
What significant development did Cell Source present in May 2026?
In May 2026, Cell Source presented breakthrough developments for mismatched donor stem cell and organ transplants and off-the-shelf CAR-T cell therapy at the LD Micro Invitational Conference in Los Angeles.
What was the outcome of Cell Source's Veto Cell clinical trial in November 2024?
In November 2024, Cell Source shared promising interim results from its groundbreaking Veto Cell clinical trial.
What was announced regarding Cell Source's private placement in January 2026?
In January 2026, Cell Source announced the closing of a private placement and the hiring of a transfer agent.

External links